XML 46 R35.htm IDEA: XBRL DOCUMENT
v3.23.3

Segment, Geographical and Other Revenue Information (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2023
Segment Reporting [Abstract] |
Schedule of Segment Reporting | The following table provides financial information by our reportable business segments along with a reconciliation to consolidated loss before income taxes (in thousands):
| Three Months Ended September 30, 2023 |  | Three Months Ended September 30, 2022
| Performance Enzymes |  | Novel Biotherapeutics |  | Total |  | Performance Enzymes |  | Novel Biotherapeutics |  | Total
Revenues: |  |  |  |  |  |  |  |  |  |  |
Product revenue | $ | 5,395 |  |  | $ | — |  |  | $ | 5,395 |  |  | $ | 28,042 |  |  | $ | — |  |  | $ | 28,042 |
Research and development revenue | 3,315 |  |  | 567 |  |  | 3,882 |  |  | 3,104 |  |  | 3,324 |  |  | 6,428 |
Total revenues | 8,710 |  |  | 567 |  |  | 9,277 |  |  | 31,146 |  |  | 3,324 |  |  | 34,470 |
Costs and operating expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of product revenue | 2,249 |  |  | — |  |  | 2,249 |  |  | 9,786 |  |  | — |  |  | 9,786 |
Research and development (1) | 8,146 |  |  | 4,377 |  |  | 12,523 |  |  | 6,782 |  |  | 13,855 |  |  | 20,637 |
Selling, general and administrative (1) | 1,748 |  |  | 386 |  |  | 2,134 |  |  | 3,791 |  |  | 888 |  |  | 4,679 |
Restructuring charges | 1,182 |  |  | 1,217 |  |  | 2,399 |  |  | — |  |  | — |  |  | — |
Asset impairment and other charges (2) | — |  |  | 778 |  |  | 778 |  |  | — |  |  | — |  |  | — |
Total segment costs and operating expenses | 13,325 |  |  | 6,758 |  |  | 20,083 |  |  | 20,359 |  |  | 14,743 |  |  | 35,102 |
Income (loss) from operations | $ | (4,615) |  |  | $ | (6,191) |  |  | (10,806) |  |  | $ | 10,787 |  |  | $ | (11,419) |  |  | (632) |
Corporate costs (3) |  |  |  |  | (22,736) |  |  |  |  |  |  | (7,947) |
Unallocated depreciation and amortization |  |  |  |  | (1,357) |  |  |  |  |  |  | (1,405) |
Loss before income taxes |  |  |  |  | $ | (34,899) |  |  |  |  |  |  | $ | (9,984) |
| Nine Months Ended September 30, 2023 |  | Nine Months Ended September 30, 2022
| Performance Enzymes |  | Novel Biotherapeutics |  | Total |  | Performance Enzymes |  | Novel Biotherapeutics |  | Total
Revenues: |  |  |  |  |  |  |  |  |  |  |
Product revenue | $ | 24,807 |  |  | $ | — |  |  | $ | 24,807 |  |  | $ | 93,376 |  |  | $ | — |  |  | $ | 93,376 |
Research and development revenue | 12,696 |  |  | 6,079 |  |  | 18,775 |  |  | 7,398 |  |  | 7,441 |  |  | 14,839 |
Total revenues | 37,503 |  |  | 6,079 |  |  | 43,582 |  |  | 100,774 |  |  | 7,441 |  |  | 108,215 |
Costs and operating expenses: |  |  |  |  |  |  |  |  |  |  |
Cost of product revenue | 9,947 |  |  | — |  |  | 9,947 |  |  | 29,577 |  |  | — |  |  | 29,577 |
Research and development (1) | 24,100 |  |  | 19,929 |  |  | 44,029 |  |  | 19,833 |  |  | 37,279 |  |  | 57,112 |
Selling, general and administrative (1) | 6,578 |  |  | 1,528 |  |  | 8,106 |  |  | 11,208 |  |  | 2,288 |  |  | 13,496 |
Restructuring charges | 1,182 |  |  | 1,362 |  |  | 2,544 |  |  | — |  |  | — |  |  | — |
Asset impairment and other charges (2) | — |  |  | 778 |  |  | 778 |  |  | — |  |  | — |  |  | — |
Total segment costs and operating expenses | 41,807 |  |  | 23,597 |  |  | 65,404 |  |  | 60,618 |  |  | 39,567 |  |  | 100,185 |
Income (loss) from operations | $ | (4,304) |  |  | $ | (17,518) |  |  | (21,822) |  |  | $ | 40,156 |  |  | $ | (32,126) |  |  | 8,030 |
Corporate costs (3) |  |  |  |  | (42,890) |  |  |  |  |  |  | (24,940) |
Unallocated depreciation and amortization |  |  |  |  | (4,302) |  |  |  |  |  |  | (3,953) |
Loss before income taxes |  |  |  |  | $ | (69,014) |  |  |  |  |  |  | $ | (20,863) |
(1) Research and development expenses and selling, general and administrative expenses exclude depreciation and amortization of finance leases. (2) Impairment charge of $0.8 million is related to the goodwill allocated to the Novel Biotherapeutics segment. (3) Corporate costs include unallocated selling, general and administrative expenses, unallocated asset impairment and restructuring charges, interest income, and other income (expense), net. The following table provides stock-based compensation expense in cluded in loss from operations (in thousands):
| Three Months Ended September 30,
| 2023 |  | 2022
| Performance Enzymes |  | Novel Biotherapeutics |  | Corporate cost |  | Total |  | Performance Enzymes |  | Novel Biotherapeutics |  | Corporate cost |  | Total
Stock-based compensation | $ | 903 |  |  | $ | (235) |  |  | $ | 1,615 |  |  | $ | 2,283 |  |  | $ | 1,593 |  |  | $ | 414 |  |  | $ | 2,524 |  |  | $ | 4,531 |
| Nine Months Ended September 30,
| 2023 |  | 2022
| Performance Enzymes |  | Novel Biotherapeutics |  | Corporate cost |  | Total |  | Performance Enzymes |  | Novel Biotherapeutics |  | Corporate cost |  | Total
Stock-based compensation | $ | 2,861 |  |  | $ | 98 |  |  | $ | 4,849 |  |  | $ | 7,808 |  |  | $ | 4,776 |  |  | $ | 1,182 |  |  | $ | 5,642 |  |  | $ | 11,600 |
Schedule of Customers that Contributed 10% or More of Total Accounts Receivable | Significant Customers Customers that each accounted for 10% or more of our total revenues were as follows:
| Percentage of Total Revenues for the
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Customer A | 20 | % |  | * |  | * |  | *
Customer B | * |  | 39 | % |  | 15 | % |  | 54 | %
Customer C | * |  | 13 | % |  | * |  | *
Customer D | * |  | * |  | 10 | % |  | *
Customer E | * |  | * |  | 10 | % |  | *
* Percentage was less than 10% |  |  |  |  |  |  |
Customers that each accounted for 10% or more of accounts receivable balances as of the periods presented as follows:
| Percentage of Accounts Receivables as of
| September 30, 2023 |  | December 31, 2022
Customer B | * |  | 53 | %
Customer D | 15 | % |  | *
Customer E | * |  | 10 | %
Customer F | 38 | % |  | *
Customer G | 17 | % |  | *
* Percentage was less than 10% |  |  |
Schedule of Revenues by Geographical Area | Geographic revenues are identified by the location of the customer and consist of the following (in thousands):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2023 |  | 2022 |  | 2023 |  | 2022
Revenues |  |  |  |  |  |  |
Americas | $ | 4,278 |  |  | $ | 4,822 |  |  | $ | 10,798 |  |  | $ | 12,167 |
EMEA | 3,191 |  |  | 5,987 |  |  | 14,630 |  |  | 14,805 |
APAC | 1,808 |  |  | 23,661 |  |  | 18,154 |  |  | 81,243 |
Total revenues | $ | 9,277 |  |  | $ | 34,470 |  |  | $ | 43,582 |  |  | $ | 108,215 |
Schedule of Long-Lived Assets by Geographical Area | Identifiable long-lived assets by location was as follows (in thousands):
| September 30, 2023 |  | December 31, 2022
United States | $ | 29,177 |  |  | $ | 61,877 |
Schedule of Intangible Assets and Goodwill | Identifiable goodwill by reporting unit was as follows (in thousands):
|  | Performance Enzymes |  | Novel Biotherapeutics |  | Total
Goodwill at January 1, 2023 |  | $ | 2,463 |  |  | $ | 778 |  |  | $ | 3,241 |
Impairment |  | — |  |  | (778) |  |  | (778) |
Goodwill at September 30, 2023 |  | $ | 2,463 |  |  | $ | — |  |  | $ | 2,463 |

X
- Definition Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the names of foreign countries in which material long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets are located, and amount of such long-lived assets located in that country or foreign geographic area. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 + Details
Name: | us-gaap_ScheduleOfEntityWideDisclosureOnGeographicAreasLongLivedAssetsInIndividualForeignCountriesByCountryTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of goodwill and intangible assets, which may be broken down by segment or major class. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 + Details
Name: | us-gaap_ScheduleOfIntangibleAssetsAndGoodwillTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 20 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-25 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-21 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482907/825-10-50-20 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-18 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-20 Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-16 Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482861/275-10-50-21 + Details
Name: | us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration